UK NICE supports use of Keytruda in untreated metastatic NSCLC.- Merck Inc.
In final guidance, The National Institute for Health and Care Excellence (NICE) has supported the routine use by the NHS of Keytruda (pembrolizumab), from Merck Inc, in adults with untreated PD-L1-positive metastatic non-small-cell lung cancer (NSCLC), who have no epidermal growth factor receptor- or anaplastic lymphoma kinase-positive mutations. NICE also suggested that Keytruda treatment should be halted after two years of uninterrupted treatment, or earlier in the event of disease progression.
NICE made the announcement after considering data from the phase III KEYNOTE-024 study, demonstrating that Keytruda extended overall survival when compared to chemotherapy (30.0 months OS with Keytruda versus 14.2 months with chemo).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.